Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
heart-1: VERVE-101 in HeFH and ASCVD
NCT05398029Phase 1Completed
- Sponsor
- Verve Therapeutics
- Start
- Jul 2022
- Primary completion
- Feb 2025
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 2
01
Overview
Phase 1, open-label trial of VERVE-101 in heterozygous familial hypercholesterolemia (HeFH) (2 arms), sponsored by Verve Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). Started Jul 2022; status: completed.
02
Drugs
VERVE-101
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT05398029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398029.